TOBACCO INTERNATIONAL

26 TOBACCO INTERNATIONAL MARCH 2016 product innovations. Dr. Richter aims to "Continue t o w o r k i n p a r t n e r s h i p w i t h o u r Analytical Development Centre to de- velop and deliver new methodologies for the characterization and quantifica- tion of emissions from next-generation products to address new challenges and knowledge gaps; Standardize our risk assessment processes and supporting data sets for next generation products as they become mainstream commer- cial products; Contribute to the devel- opment of global voluntary and regula- tory product standards for e-cigarettes and other emerging product categories; Quantify the risks and potential tox- icant reduction benefits of next-gen- eration products with use of the latest scientific data, in the context of tobac- co harm reduction and; Continue to publish and communicate externally on our approaches to the risk assess- ment of next-generation products to enable dialogue and engagement with scientists and regulators." • Tobacco Heating Products • Eliminating Combustion To Potentially Reduce Risk Dr. Chuan Liu, PhD., Head of Tobacco Heating Product Science D r . L i u h o l d s a PhD. in ma- t e r i a l s s c i e n c e from Cambridge University. Since joining BAT in 2000, Dr. Liu be- come a key expert on pyrolysis, smoke formation and toxi- cant reduction technologies for cigarettes. Since 2014, Dr. Liu has been the lead sci- entist for BAT's tobacco-heating products, ensuring high-quality standards of re- search for this emerging product category. "Attempts to selectively modify the complex combustion process in conven- tional cigarettes have not been successful. Although a reduction in toxicant expo- sure was achieved, the biological impact of these reductions was unclear. To re- duce toxicant formation but retain a taste resembling cigarette smoke, therefore, we have been developing tobacco heating products (THPs) that heat tobacco to between 200°C and 300°C, a temperature range sufficient to vaporize the nicotine (and some other volatile compounds) into an inhalable aerosol stream, but not enough to burn the tobacco and cause pyrolysis or combustion." • Electronic Cigarettes • Rapid Evolution Presents New Challenges Dr. Kevin McAdam, Head of Nicoventures Research A n e x p e r i e n c e d c h e m i s t , D r . M c A d a m h a s spent the past 30 years researching tobacco harm re- duction. He spe- cialized in com- bustion chemistry during his PhD., and atmospheric pollution during his postdoctoral training. Since joining BAT in 1987, he has worked on the science underpinning tobacco harm re- duction, including smokeless tobacco products, reduced-toxicant cigarettes, tobacco-heating products, and e-cig- arettes. Dr. McAdams heads BAT's Nicoventures research program. "To promote good practice across the industry, we believe it is our responsibility to share our knowledge and contribute to the science of vaping. Our scientists have presented our scientific insights and approach to stewardship of e-cigarette fla- vors at major science conferences hosted by the US Food and Drug Administration (FDA), the Society for Research on Nicotine and Tobacco, and the Global Forum on Nicotine workshops. We also recently published the first practical guide on how to develop flavors responsibly, based on sound toxicological principles." • Product Testing • Building the Evidence Base Dr. Marianna Gaça, PhD., Pre- Clinical Assessment Manager Dr. Gaça holds a PhD., in cell a n d m o l e c u l a r m e d i c i n e a n d d i d h e r p o s t - d o c t o r a l w o r k a t Y a l e S c h o o l of Medicine and University of Pennsylvania before join- ing BAT in 2004. She has held various roles investigating the biological effects of cigarette smoke, including the de- velopment of in vitro models of tobac- co related-diseases and whole-smoke exposure systems. Dr. Gaça has also represented BAT (and the wider tobac- co industry) at board level on many in vitro societies, including IVTIP and ASCCT. She is passionate about the development and application of in vitro models as alternatives to product as- sessment in animals. "Although some of the toxicity as- says we employ are commonly used by the tobacco industry and the meth- odologies are consolidated through CORESTA, our researchers are adapt- ing them where necessary and appli- cable to assess next generation prod- ucts more accurately. For example, we recently modified the Ames test to enable the assessment of aerosols and whole smoke, and have applied existing irritancy testing standards to the testing of e-cigarette vapor in the EpiAirwayTM model4, showing e-cig- arette vapor producing results similar to those for air." • Quantifying Risk • Improved Understanding of Toxicants and Disease Fiona Cunningham, Combustible Toxicology Scientist Fiona joined BAT's in vitro models team in 2005, with a BSc in chemis- MANUFACTURER PROFILE

• Cover